Amanda Nickles Fader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11336948/publications.pdf

Version: 2024-02-01

58 papers 4,711 citations

36 h-index 51 g-index

60 all docs 60 docs citations

60 times ranked

4664 citing authors

#	Article	IF	CITATIONS
1	Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 170-199.	4.9	488
2	Oncologic and Reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A systematic review. Gynecologic Oncology, 2012, 125, 477-482.	1.4	348
3	Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecologic Oncology, 2009, 114, 121-127.	1.4	301
4	Laparoendoscopic single-site surgery (LESS) in gynecologic oncology: Technique and initial report. Gynecologic Oncology, 2009, 114, 157-161.	1.4	293
5	Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 395-404.	4.9	250
6	Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) reviewa ⁻ †. Gynecologic Oncology, 2009, 115, 142-153.	1.4	247
7	Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2017, 216, 459-476.e10.	1.3	241
8	Platinum/taxaneâ€based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer, 2009, 115, 2119-2127.	4.1	150
9	A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. Gynecologic Oncology, 2014, 134, 281-286.	1.4	134
10	Robotic-Assisted Laparoendoscopic Single-Site Surgery in Gynecology: Initial Report and Technique. Journal of Minimally Invasive Gynecology, 2009, 16, 589-591.	0.6	128
11	An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecologic Oncology, 2009, 115, 244-248.	1.4	122
12	Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation. American Journal of Obstetrics and Gynecology, 2010, 203, 501.e1-501.e6.	1.3	113
13	Uterine Neoplasms, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 248-280.	4.9	113
14	Uterine Papillary Serous Carcinoma. Clinical Obstetrics and Gynecology, 2011, 54, 278-291.	1.1	107
15	Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Current Opinion in Obstetrics and Gynecology, 2010, 22, 21-29.	2.0	106
16	Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: Surgical outcomes and learning curve analysis. Gynecologic Oncology, 2010, 119, 43-47.	1.4	97
17	Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centers. Gynecologic Oncology, 2012, 126, 180-185.	1.4	97
18	A multi-institutional cohort study of adjuvant therapy in stage l–II uterine carcinosarcoma. Gynecologic Oncology, 2012, 127, 22-26.	1.4	94

#	Article	IF	Citations
19	Laparoendoscopic single-site (LESS) surgery in patients with benign adnexal disease. Fertility and Sterility, 2010, 93, 2074.e7-2074.e10.	1.0	93
20	Understanding the "Scope―of the Problem: Why Laparoscopy Is Considered Safe during the COVID-19 Pandemic. Journal of Minimally Invasive Gynecology, 2020, 27, 789-791.	0.6	91
21	Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecologic Oncology, 2009, 112, 558-562.	1.4	78
22	Survival in Women With Grade 1 Serous Ovarian Carcinoma. Obstetrics and Gynecology, 2013, 122, 225-232.	2.4	78
23	Comparison of Single-Port Laparoscopy, Standard Laparoscopy, and Robotic Surgery in Patients with Endometrial Cancer. Annals of Surgical Oncology, 2012, 19, 1583-1588.	1.5	65
24	Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all. Gynecologic Oncology, 2015, 136, 373-383.	1.4	64
25	Single-Port Laparoscopic Pelvic and Para-Aortic Lymph Node Sampling or Lymphadenectomy. International Journal of Gynecological Cancer, 2010, 20, 1268-1273.	2.5	60
26	Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1321-1331.	4.9	58
27	Laparoendoscopic single-site and natural orifice surgery in gynecology. Fertility and Sterility, 2010, 94, 2497-2502.	1.0	52
28	High-grade endometrial cancer: Revisiting the impact of tumor size and location on outcomes. Gynecologic Oncology, 2014, 132, 44-49.	1.4	51
29	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 2014, 132, 560-565.	1.4	50
30	Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecologic Oncology, 2008, 109, 33-38.	1.4	48
31	Early stage uterine serous carcinoma: Management updates and genomic advances. Gynecologic Oncology, 2013, 129, 244-250.	1.4	48
32	Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer. Frontiers in Oncology, 2016, 6, 102.	2.8	45
33	Laparoendoscopic single-site surgery in gynaecology: A new frontier in minimally invasive surgery. Journal of Minimal Access Surgery, 2011, 7, 71.	0.7	42
34	Laparoendoscopic Single-site Radical Hysterectomy With Pelvic Lymphadenectomy: Initial Multi-institutional Experience for Treatment of Invasive Cervical Cancer. Journal of Minimally Invasive Gynecology, 2014, 21, 394-398.	0.6	42
35	Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence. Gynecologic Oncology, 2010, 116, 10-14.	1.4	40
36	Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. International Journal of Women's Health, 2016, 8, 151.	2.6	38

#	Article	IF	CITATIONS
37	Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecologic Oncology, 2014, 132, 33-37.	1.4	33
38	CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Research, 2010, 30, 4791-8.	1.1	32
39	Laparoendoscopic single-site surgery (LESS) radical hysterectomy for the treatment of early stage cervical cancer. Gynecologic Oncology, 2013, 129, 241-243.	1.4	25
40	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology Journal of Clinical Oncology, 2016, 34, 3003-3003.	1.6	24
41	Lifestyle and Weight Management Counseling in Uterine Cancer Survivors: A Study of the Uterine Cancer Action Network. International Journal of Gynecological Cancer, 2015, 25, 1285-1291.	2.5	19
42	A 14-Week Abdominal Pregnancy After Total Abdominal Hysterectomy. Obstetrics and Gynecology, 2007, 109, 519-521.	2.4	17
43	Abnormal Cervical Cytology in the Diagnosis of Uterine Papillary Serous Carcinoma: Earlier Detection of a Poor Prognostic Cancer Subtype?. Acta Cytologica, 2011, 55, 255-260.	1.3	17
44	The Utility of Sentinel Lymph Node Mapping in High-Grade Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 1416-1421.	2.5	16
45	Laparoendoscopic Single-Site Surgery for Management of Ovarian Endometriomas. Journal of the Society of Laparoendoscopic Surgeons, 2014, 18, 191-196.	1.1	13
46	An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. Journal of Minimally Invasive Gynecology, 2016, 23, 303-308.	0.6	13
47	Symptomatic vaginal bleeding in a postmenopausal woman: a case report of pancreatic adenocarcinoma metastasizing exclusively to the vagina. American Journal of Obstetrics and Gynecology, 2007, 197, e8-e9.	1.3	9
48	A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum Journal of Clinical Oncology, 2021, 39, TPS5601-TPS5601.	1.6	7
49	PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine. Gynecologic Oncology, 2021, 163, 11-13.	1.4	7
50	Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma. Journal of Gynecologic Oncology, 2012, 23, 288.	2.2	4
51	Updates on uterine papillary serous carcinoma. Expert Review of Obstetrics and Gynecology, 2009, 4, 647-657.	0.4	2
52	The expanding spectrum of robotic gynecologic surgery: A review. Middle East Fertility Society Journal, 2012, 17, 70-78.	1.5	1
53	E-NOTES: Promising minimal surgical approach for gynecologic disease. Gynecologic Oncology, 2009, 115, 321.	1.4	0
54	RE: "Stage 1, Grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence― Gynecologic Oncology, 2010, 117, 507-508.	1.4	0

#	Article	IF	CITATIONS
55	Treatment of uterine papillary serous carcinoma. Expert Opinion on Orphan Drugs, 2013, 1, 819-827.	0.8	O
56	Effect of lymphopenia on survival in women with cervical cancer treated with primary chemoradiation Journal of Clinical Oncology, 2014, 32, e16507-e16507.	1.6	0
57	The "little big things― A qualitative study of ovarian cancer survivors and their experiences with the health care system Journal of Clinical Oncology, 2016, 34, 252-252.	1.6	O
58	Treatment of gynecologic cancers in HIV+ women Journal of Clinical Oncology, 2016, 34, e17064-e17064.	1.6	0